ADMA Biologics Inc. (NASDAQ:ADMA) and IVERIC bio Inc. (NASDAQ:ISEE) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics Inc. | 4 | 11.74 | N/A | -1.34 | 0.00 |
| IVERIC bio Inc. | 1 | 0.00 | N/A | 1.54 | 0.77 |
Table 1 demonstrates ADMA Biologics Inc. and IVERIC bio Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 provides us ADMA Biologics Inc. and IVERIC bio Inc.’s return on equity, net margins and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics Inc. | 0.00% | -205.4% | -62.4% |
| IVERIC bio Inc. | 0.00% | 97.6% | 46% |
Risk and Volatility
ADMA Biologics Inc.’s 2.7 beta indicates that its volatility is 170.00% more volatile than that of S&P 500. Competitively, IVERIC bio Inc. is 15.00% more volatile than S&P 500, because of the 1.15 beta.
Liquidity
ADMA Biologics Inc.’s Current Ratio is 4.6 while its Quick Ratio is 2.4. On the competitive side is, IVERIC bio Inc. which has a 12 Current Ratio and a 12 Quick Ratio. IVERIC bio Inc. is better positioned to pay off short and long-term obligations compared to ADMA Biologics Inc.
Analyst Ratings
In next table is given ADMA Biologics Inc. and IVERIC bio Inc.’s ratings and recommendations.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| ADMA Biologics Inc. | 0 | 0 | 5 | 3.00 |
| IVERIC bio Inc. | 0 | 0 | 0 | 0.00 |
The consensus price target of ADMA Biologics Inc. is $10.9, with potential upside of 234.36%.
Insider & Institutional Ownership
ADMA Biologics Inc. and IVERIC bio Inc. has shares owned by institutional investors as follows: 50.4% and 61.9%. Insiders owned roughly 7.7% of ADMA Biologics Inc.’s shares. Insiders Competitively, owned 0.3% of IVERIC bio Inc. shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| ADMA Biologics Inc. | -2.43% | -1.9% | -19.2% | 14.92% | -42.36% | 51.46% |
| IVERIC bio Inc. | 0% | -6.3% | -10.53% | -4.03% | -50.83% | -0.83% |
For the past year ADMA Biologics Inc. has 51.46% stronger performance while IVERIC bio Inc. has -0.83% weaker performance.
Summary
On 5 of the 9 factors IVERIC bio Inc. beats ADMA Biologics Inc.
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
